BiotechTube

Vigabatrin

ApprovedWithdrawn
0 watching 0 views this week🔥 Hot
82
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Infantile Spasms

Conditions

Infantile Spasms

Trial Timeline

Jun 1, 2012 → —

NCT ID
NCT01413711

About Vigabatrin

Vigabatrin is a approved stage product being developed by Lundbeck for Infantile Spasms. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01413711. Target conditions include Infantile Spasms.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (2)

NCT IDPhaseStatus
NCT01413711ApprovedWithdrawn
NCT01266291ApprovedTerminated

Competing Products

16 competing products in Infantile Spasms

See all competitors
ProductCompanyStageHype Score
TSHA-101Taysha Gene TherapiesPhase 1/2
36
MAS825 + PlaceboNovartisPhase 2
52
alglucosidase alfa + alglucosidase alfaSanofiApproved
84
MyozymeSanofiPhase 2
51
Bacillus Clausii Multi ATB Resist + PlaceboSanofiApproved
84
RadiprodilUCBPhase 2
49
Larotrectinib (Vitrakvi, BAY2757556) + Standard of CareBayerPre-clinical
20
Sabril®LundbeckPre-clinical
20
NusinersenBiogenPre-clinical
20
GWP42003-PJazz PharmaceuticalsPhase 3
74
GWP42003-PJazz PharmaceuticalsPhase 3
74
Cerliponase AlfaBioMarin PharmaceuticalPre-clinical
20
Cholic AcidsMirum PharmaceuticalsPhase 3
74
Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3
74
ATB200 + AT2221Amicus TherapeuticsPre-clinical
20
RP-L401Rocket PharmaceuticalsPhase 1
25

Other Products from Lundbeck

VortioxetineApproved
82
memantine + memantine + placeboApproved
82
escitalopram + escitalopramApproved
82
BrexpiprazoleApproved
82
losartan (drug)Approved
82